异动解读 | ADMA生物制品公司季报符合预期,股价却意外大跌10.73%

异动解读
Aug 07

生物制药公司ADMA Biologics Inc(ADMA)在发布最新季度财报后,股价在周三夜盘交易中意外大跌10.73%,引发市场关注。尽管公司业绩基本符合预期,但投资者似乎对某些方面仍持谨慎态度。

根据公司公布的财报,截至6月30日的季度调整后每股收益为14美分,与分析师预期一致,高于去年同期的13美分。营收同比增长13.8%,达到1.2198亿美元,但略低于分析师预期的1.2267亿美元。公司报告的季度净收入为3422万美元。值得注意的是,ADMA Biologics的股价在本季度曾上涨4.1%,今年迄今为止更是上涨了10.6%。

尽管公司业绩总体表现不俗,但夜盘大跌可能反映了投资者对未来增长前景的担忧。分析师指出,过去三个月,对该公司的平均盈利预期下降了约16%,这可能是导致股价下跌的一个因素。此外,虽然华尔街分析师对ADMA的平均评级仍为"买入",12个月目标价中位数为31.00美元,较之前交易日收盘价高出38.8%,但投资者似乎选择了更为谨慎的态度。这种反应可能也与近期股价涨幅较大有关,部分投资者可能选择获利了结。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10